--- title: "Highland Capital Management LLC Trims Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)" description: "Highland Capital Management LLC reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.6% in the second quarter, according to a recent 13F filing. Following the sale of 2,480 shares, they no" type: "news" locale: "en" url: "https://longbridge.com/en/news/212555851.md" published_at: "2024-08-26T13:49:09.000Z" --- # Highland Capital Management LLC Trims Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) > Highland Capital Management LLC reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.6% in the second quarter, according to a recent 13F filing. Following the sale of 2,480 shares, they now own 29,990 shares valued at $201,000. Other hedge funds have also adjusted their holdings, showing significant activity around Jazz Pharmaceuticals. Analysts have mixed ratings, but the consensus remains "Moderate Buy" with a target price of $118.07. The stock's performance shows a market cap of $6.24 billion and trades between $54.06 and $70.70 over the past year. Highland Capital Management LLC decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 7.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,990 shares of the specialty pharmaceutical company's stock after selling 2,480 shares during the quarter. Highland Capital Management LLC's holdings in Jazz Pharmaceuticals were worth $3,201,000 as of its most recent filing with the Securities and Exchange Commission. Get **Jazz Pharmaceuticals** alerts: - Zymeworks Offers Hope for More than Just Long-Term Investors A number of other hedge funds have also recently modified their holdings of JAZZ. Rise Advisors LLC grew its position in Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 203 shares during the period. Versant Capital Management Inc lifted its stake in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after purchasing an additional 269 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after purchasing an additional 116 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Cape Investment Advisory Inc. raised its holdings in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock valued at $36,000 after buying an additional 292 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock. ## Wall Street Analyst Weigh In Several research analysts have weighed in on the stock. Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an "outperform" rating for the company in a research note on Thursday, August 1st. Cantor Fitzgerald restated an "overweight" rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a research report on Monday, August 19th. Finally, HC Wainwright restated a "buy" rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $173.07. - Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game) **Check Out Our Latest Stock Analysis on JAZZ** ## Jazz Pharmaceuticals Stock Performance Shares of JAZZ stock opened at $114.73 on Monday. The stock's 50-day moving average is $109.11 and its two-hundred day moving average is $112.99. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $146.70. The firm has a market cap of $7.24 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 1.76 and a beta of 0.58. ## Jazz Pharmaceuticals Profile (Free Report) Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. ## Further Reading - Five stocks we like better than Jazz Pharmaceuticals - REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today - Eli Lilly’s Path to the Next Trillion Market Capitalization - Find and Profitably Trade Stocks at 52-Week Lows - Mobileye Global: CEO Makes $10 Million Bet on Future Strength - What is the Shanghai Stock Exchange Composite Index? - 3 Stocks Increasing Dividend Payouts Ahead of Interest Rate Cuts *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* → The only AI company to buy (From Porter & Company) (Ad)## Should you invest $1,000 in Jazz Pharmaceuticals right now? Before you consider Jazz Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list. While Jazz Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [JAZZ.US - Jazz Pharma](https://longbridge.com/en/quote/JAZZ.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 分析爵士制药（JAZZ）在 Ziihera 第三阶段胃食管癌试验取得积极结果后的估值 | 爵士制药（Jazz Pharmaceuticals，JAZZ）因其针对 HER2 的药物 Ziihera 在胃食管癌的第三阶段临床试验中取得积极结果而受到关注，显示出显著的生存率改善。该股票在过去 90 天内回报率为 22.6%，在过去一年 | [Link](https://longbridge.com/en/news/271933572.md) | | 分析师们对爵士制药股票的评价 | 分析师在过去三个月对爵士制药（NASDAQ:JAZZ）提供了不同的评级，共有 11 位分析师给出了见解。12 个月的平均目标价为 206.00 美元，比之前的目标上涨了 16.68%。主要分析师提高了他们的评级和目标价，显示出积极的市场情绪 | [Link](https://longbridge.com/en/news/272265895.md) | | 爵士制药在最新的演示中展示了其在罕见病领域的突破以及增长战略 | 爵士制药公司在第 44 届摩根大通医疗健康大会上展示了其在罕见疾病治疗领域的成就和增长战略。公司强调了 FDA 的批准以及一款用于广泛期小细胞肺癌药物的成功上市，销售额超过 10 亿美元。它还收购了 Modeyso，以增强神经肿瘤学的专业知 | [Link](https://longbridge.com/en/news/272449426.md) | | 爵士制药完成了对 Chimerix 的收购 | 爵士制药已收购 Chimerix，并将其纳入公司的战略中。此次收购包括第三阶段 ACTION 试验，Modeyso 的批准提前于预期。预计 2025 年的收入接近 5000 万美元，预计到 2026 年底或 2027 年初将有更多数据发布。 | [Link](https://longbridge.com/en/news/272282470.md) | | 爵士制药宣布 Ziihera 三期试验取得了积极的疗效结果 | 爵士制药 PLC：ZIIHERA®（ZANIDATAMAB-HRII）联合疗法在一线 HER2+ 局部晚期或转移性胃食管癌中取得了前所未有的结果，包括超过两年的中位总生存期获益。爵士制药 PLC：目前预计 ZIIHERA 加化疗的额外计划中 | [Link](https://longbridge.com/en/news/271691426.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.